ALCON INC (ALC) Stock News
NYSE:ALC - New York Stock Exchange, Inc. - CH0432492467 - Common Stock - Currency: USD
ALC Latest News, Press Relases and Analysis
COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?
Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Alcon Stock Rises Following the FDA Approval of TRYPTYR
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls
UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls
Company News for May 15, 2025
Companies in The News Are: ARCO,DT,EXEL,ALC
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
ALC ends the first quarter of 2025 on a disappointing note.
Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Do Options Traders Know Something About Alcon Stock We Don't?
Investors need to pay close attention to ALC stock based on the movements in the options market lately.
Top Research Reports for Texas Instruments, Boeing & NextEra Energy
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), The Boeing Company (BA) and NextEra Energy, Inc. (NEE).
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Alcon Announces Results of 2025 Annual General Meeting
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC)
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The majority of growth indexes entered correction territory during the quarter, due to pressure from the chaotic tariff implementation, concerns about a weakening U.S. economy, and increased inflation. […]
Mentions: TSLA
Alcon Publishes Agenda for 2025 Annual General Meeting
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
Alcon to Host 2025 Capital Markets Day
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
